Wall Street RegretsThe regret calculator.

What if you'd held NKTR?

A $1,000 investment in Nektar Therapeutics (NKTR) at the month-end close of 1994-05 would be worth $1,353 at the close of 2026-08 — +35.3% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $16,885.

$1,000 since 1994$1,353Total return+35.3%Multiple1.4×CAGR+0.9%

Your scenario

Dates resolve to the nearest month-end close.
Leave empty for "held until today".
Invested at each month-end. Starts on the buy date.

Result

Worth$1,353Gain+$353 (+35.3%)Multiple1.4×CAGR+0.9%

    If you'd bought $1,000 at the start of each year

    Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.

    2000$2382001$1002002$2732003$6282004$3732005$2512006$3082007$3332008$7562009$9122010$5442011$3952012$9062013$6842014$4472015$3272016$3012017$4132018$84.932019$1542020$2352021$2982022$3752023$2,2442024$9,0572025$5,4542026$1,799

    Every year, $1,000 from 1994

    YearValue of $1,000Year return
    1994$1,000
    1995$1,054+5.4%
    1996$1,635+55.1%
    1997$2,811+71.9%
    1998$3,567+26.9%
    1999$4,601+29.0%
    2000$10,918+137.3%
    2001$4,011-63.3%
    2002$1,747-56.4%
    2003$2,942+68.4%
    2004$4,376+48.7%
    2005$3,559-18.7%
    2006$3,288-7.6%
    2007$1,451-55.9%
    2008$1,202-17.1%
    2009$2,015+67.6%
    2010$2,778+37.9%
    2011$1,211-56.4%
    2012$1,602+32.3%
    2013$2,454+53.2%
    2014$3,351+36.6%
    2015$3,643+8.7%
    2016$2,653-27.2%
    2017$12,912+386.7%
    2018$7,107-45.0%
    2019$4,668-34.3%
    2020$3,675-21.3%
    2021$2,921-20.5%
    2022$489-83.3%
    2023$121-75.2%
    2024$201+66.1%
    2025$609+203.1%
    2026$1,097+79.9%

    Best and worst month-end to buy

    The best single month-end close to have bought NKTR was 2023-10 ($7.05): $1,000 then is $10,791 today. The worst was 2018-03 ($1,594): $1,000 then is $47.73.

    FAQ

    What would $1,000 in NKTR be worth today?

    A $1,000 investment in Nektar Therapeutics (NKTR) at the start of 1994 would be worth about $1,353 today, a total return of +35.3%. Dividends are reinvested in these figures.

    What were the best and worst years for NKTR?

    Nektar Therapeutics (NKTR)'s strongest calendar year since 1994 was 2017, a +386.7% return — $1,000 held through that year became about $4,867 by year-end. Its weakest year was 2022, at -83.3%.

    Does the calculator include dividends and splits?

    Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.

    How much would $100 per month in NKTR have grown?

    Investing $100 at the end of every month since 1994-05 would have grown to about $38,343 on $38,800 invested.

    Did NKTR beat the S&P 500?

    Over the same period, $1,000 in the S&P 500 index would be worth $16,885. NKTR trailed the S&P 500 by +92.0% in total return.

    Is this investment advice?

    No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.

    Methodology

    Nektar Therapeutics (NKTR) historical total-return data from 1994-05 to 2026-08, reduced to month-end closes for the tables above.

    Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.

    Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.

    Full methodology →

    What if you'd held…

    Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.